Vanguard Capital Management
MBRX icon

Vanguard Capital Management’s Moleculin Biotech MBRX Stock Holding History

Vanguard Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118K Buy
42,215
+28,346
+204% +$72.4K ﹤0.01% 3866
2026
Q1 		$31.8K Buy
+13,869
New +$45.9K ﹤0.01% 3957

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management's MBRX Position: Q2 2026 in Review

Vanguard Capital Management increased its Moleculin Biotech (MBRX) stake by 204% in Q2 2026, buying an estimated $72.4K and bringing the position to 42,215 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3866.

Vanguard Capital Management first reported a position in MBRX in Q1 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Vanguard Capital Management held 42,215 shares of Moleculin Biotech worth $118K as of Q2 2026.
  • Vanguard Capital Management bought 28,346 Moleculin Biotech shares in Q2 2026, an estimated $72.4K.
  • Moleculin Biotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3866 holding.
  • Vanguard Capital Management first reported a position in Moleculin Biotech in Q1 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.